文献速递免疫规划妇幼与学校卫生

日本孕妇与新生儿百日咳、白喉、破伤风抗体血清阳性率:为孕前或产前接种DTaP疫苗提供初步数据

Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society.
PubMed 文献 · Vaccine · 2022-10-28

研究调查日本孕妇与新生儿百日咳、白喉、破伤风抗体血清阳性率,评估孕前或产前接种DTaP疫苗的必要性。孕妇百日咳毒素IgG与丝状血凝素IgG血清阳性率分别为69%和75%,白喉IgG和破伤风IgG均为100%。孕早期PT-IgG/FHA-IgG滴度与脐血滴度显著相关(P<0.001),至少30%研究人群未达到为新生儿和自身提供充足百日咳免疫的阈值。

要点

  • 日本孕妇百日咳PT-IgG和FHA-IgG血清阳性率分别为69%和75%,均低于白喉和破伤风IgG的100%。
  • 孕早期PT-IgG/FHA-IgG滴度与脐血PT-IgG/FHA-IgG滴度显著相关(P<0.001)。
  • 至少30%研究人群未达到提供充足百日咳免疫的阈值,日本批准的DTaP疫苗缺乏孕期安全性信息。

核心结论

  • 日本孕妇百日咳血清阳性率约70%,低于白喉和破伤风。
  • 孕早期母体抗体水平充足时,胎儿获得的针对百日咳的被动免疫更高。
  • 至少30%研究人群未达到为新生儿和自身提供充足百日咳免疫的阈值。

研究设计与样本

  • 研究收集孕早期、产后1周内及脐血的母体PT-IgG(EIA)和FHA-IgG(EIA),以及初乳百日咳-IgA(ELISA)、白喉-IgG(EIA)、破伤风-IgG(EIA)和孕早期血样。
  • 研究纳入日本孕妇与新生儿,为孕前或产前接种DTaP疫苗提供初步数据。

主要发现

  • 母体PT-IgG和FHA-IgG血清阳性率分别为69%和75%。
  • 所有受试者白喉-IgG和破伤风-IgG均为阳性(100%)。
  • 孕早期PT-IgG/FHA-IgG抗体滴度与脐血PT-IgG/FHA-IgG滴度显著相关(P<0.001)。
  • 至少30%研究人群未达到为新生儿和自身提供充足百日咳免疫的阈值。

临床怎么用

  • 日本批准的無细胞百日咳疫苗(DTaP)缺乏孕期安全性信息,作者提出引入孕前接种DTaP可能是及时实施产前無细胞百日咳疫苗接种的解决方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An increasing number of countries have been introducing acellular pertussis vaccination during pregnancy for the prevention of neonatal pertussis. In response to the fact that infantile pertussis cases of 0-5 months age groups remained unchanged despite the universal vaccination program, prenatal pertussis vaccination has been a rising issue in Japan. Hence, we investigated the seroprevalence of pertussis, diphtheria, and tetanus antibodies in Japanese pregnant women and neonates, and evaluated the necessity of diphtheria-tetanus-acellular pertussis (DTaP) vaccination during the preconception or prenatal period. Maternal PT-IgG (EIA) and FHA-IgG (EIA) for the first trimester, within 1 week after delivery, and cord blood were collected, along with colostrum pertussis-IgA (ELISA), diphtheria-IgG (EIA), tetanus-IgG (EIA), and blood samples from the first trimester. The maternal seroprevalence of PT-IgG and FHA-IgG was 69 % and 75 %, respectively. All tested participants were positive for diphtheria-IgG and tetanus-IgG (100 %). First trimester PT-IgG/FHA-IgG antibody titers were significantly associated with cord blood PT-IgG/FHA-IgG titers (P < 0.001). We found that pertussis seroprevalence among pregnant Japanese women was approximately 70 %. The antibody seropositivity rate of pertussis was lower than that of diphtheria and tetanus. Fetal acquired passive immunity against pertussis is higher when the level of maternal antibody in the first trimester is sufficient. At least 30 % of study population did not reach to the threshold value to provide sufficient pertussis immunity for the neonates and themselves. The acellular pertussis vaccine (DTaP) approved in Japan lacks safety information for pregnancy, hence, a solution for prompt administration of prenatal acellular pertussis vaccination might be introducing DTaP in the preconception period.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tsurane K, Umehara N, Nakayama T, et al. Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society. Vaccine. 2022. PMID: 36404430. doi:10.1016/j.vaccine.2022.09.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。